Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06075537
PHASE2/PHASE3

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Sponsor: Denali Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a multiregional open-label extension (OLE) to assess the safety, tolerability, and efficacy of long-term treatment with tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant intravenous (IV) enzyme replacement therapy (ERT) for Hunter syndrome (MPS II). Participants who complete at least through the Week 49 visit in Study DNLI-E-0002 and do not discontinue study intervention early and participants who complete Study DNLI-E-0007 will be enrolled in this OLE. All participants will receive DNL310 for up to 5 years from the time of entry in this OLE. Participants, site staff, and the Sponsor will remain blinded to the original treatment assignment for participants entering this OLE from Study DNLI-E-0007.

Official title: An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Key Details

Gender

All

Age Range

Any - 18 Years

Study Type

INTERVENTIONAL

Enrollment

99

Start Date

2023-09-20

Completion Date

2027-06

Last Updated

2026-03-11

Healthy Volunteers

No

Interventions

DRUG

tividenofusp alfa

Intravenous repeating dose

Locations (25)

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States

UNC Children's Research Institute

Chapel Hill, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

The University of Texas Medical School at Houston

Houston, Texas, United States

Huntsman Cancer Hospital

Salt Lake City, Utah, United States

Sanatorio Mater Dei

Buenos Aires, Argentina

Universitair Ziekenhuis Antwerpen

Edegem, Antwerpen, Belgium

UZ Brussel

Jette, Belgium

University of Alberta - Faculty of Medicine & Dentistry

Edmonton, Alberta, Canada

Hospital for Sick Children

Toronto, Ontario, Canada

McGill University Health Center

Montreal, Quebec, Canada

Vseobecna Fakultni Nemocnice V Praze

Prague, Czechia

Hopital Jeanne De Flandre - Metabolic Diseases Unit

Lille, France

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany

SpinCS GmbH

Höchheim, Germany

ASST di Cremona

Cremona, Italy

Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia

Udine, Italy

Erasmus Medical Center - Sophia Children's Hospital

Rotterdam, Netherlands

Hospit U. Vall d'Hebron - PPDS

Barcelona, Spain

Drottning Silvias Barn Och Ungdomssjukhus

Gothenburg, Sweden

University Medical Faculty Balcali Hospital

Adana, Turkey (Türkiye)

Gazi Universitesi Tip Fakultes

Ankara, Turkey (Türkiye)

Birmingham Women's and Children's NHS Foundation Trust

Birmingham, United Kingdom

Great Ormond Street Hospital

London, United Kingdom